Research output per year
Research output per year
Fingerprint
Dive into the research topics where Julia Katharina Schwarze is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors
Vounckx, M., Tijtgat, J., Stevens, L., Dirven, I., Ilsen, B., Vandenbroucke, F., Raeymaeckers, S., Vekens, K., Forsyth, R., Geeraerts, X., Van Riet, I., Schwarze, J. K., Tuyaerts, S., Decoster, L., De Ridder, M., Dufait, I. & Neyns, B., 2 Jul 2024, In: Cancer Immunol Immunother. 73, 9, 8 p., 167.Research output: Contribution to journal › Article › peer-review
Open Access -
ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis
Arrieta, V. A., Duerinck, J., Burdett, K. B., Habashy, K. J., Geens, W., Gould, A., Schwarze, J. K., Dmello, C., Kim, K-S., Saganty, R., Chen, L., Moscona, A., McCord, M., Lee-Chang, C., Horbinski, C. M., Zhang, H., Stupp, R., Neyns, B. & Sonabend, A. M., 15 Jan 2024, In: Clinical Cancer Research. 30, 2, p. 379-388 10 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Citations (Scopus)106 Downloads (Pure) -
Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition
Geens, W., Vanlaer, N., Nijland, L., Van Laere, S., Schwarze, J. K., Bruneau, M., Neyns, B., Rogiers, A. & Duerinck, J., 2024, In: Journal of Neuro-Oncology. 168, 1, p. 159-169 11 p.Research output: Contribution to journal › Article › peer-review
-
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
Tijtgat, J., Geeraerts, X., Boisson, A., Stevens, L., Vounckx, M., Dirven, I., Schwarze, J. K., Raeymaeckers, S., Forsyth, R., Van Riet, I., Tuyaerts, S., Willard-Gallo, K. & Neyns, B., 11 Jan 2024, In: Journal for ImmunoTherapy of Cancer. 12, 1, 12 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)
Awada, G., Dirven, I., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kockx, M. & Neyns, B., 15 Feb 2024, In: JCO precision oncology. 8, p. 1-10 10 p., PO.23.00493.Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus)25 Downloads (Pure)
Prizes
-
Best Poster Award
Awada, Gil (Recipient), Özdemir, Ibrahim (Recipient), Schwarze, Julia Katharina (Recipient), Daeninck, Emma (Recipient), Gondry, Odrade (Recipient), Jansen, Y. (Recipient), Seremet, T. (Recipient), Keyaerts, Marleen (Recipient), Everaert, Hendrik (Recipient) & Neyns, Bart (Recipient), 15 Dec 2018
Prize: Prize (including medals and awards)
-
Oral presentation 3rd prize
Schwarze, Julia Katharina (Recipient), 7 Feb 2020
Prize: Prize (including medals and awards)
-
Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent glioblastoma.
Wietse Geens (Speaker), Stephanie Du Four (Contributor), S VAN LAERE (Contributor), Julia Katharina Schwarze (Contributor), Gil Awada (Contributor), Michaël Bruneau (Contributor), Jens Tijtgat (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor) & Bart Neyns (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Speaker)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference